NCT01237873View on ClinicalTrials.gov

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Essential Hypertension
Interventions
DRUG

Ali/Amlo 150/2.5 mg

Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg

Trial Locations (13)

231-0023

Novartis Investigative Site, Yokohama

343-0826

Novartis Investigative Site, Koshigaya

133-0061

Novartis Investigative Site, Edogawa-ku

124-0024

Novartis Investigative Site, Katsushika-ku

204-0021

Novartis Investigative Site, Kiyose

186-0001

Novartis Investigative Site, Kunitachi

105-7390

Novartis Investigative Site, Minato-ku

108-0075

Novartis Investigative Site, Minato-ku

143-0023

Novartis Investigative Site, Ōta-ku

150-0002

Novartis Investigative Site, Shibuya-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

190-0013

Novartis Investigative Site, Tachikawa

171-0021

Novartis Investigative Site, Toshima-ku

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY